For instance, CAEs of VEGF inhibition by bevacizumab include not only arterial hypertension and nephrotoxicity [80,81,82,83], but also extend to thromboembolic events and acute vascular morbidities [80]. The gene discussed is VEGFA; the disease is Hypertension.